Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion, Offering $31.50/Share Cash

summarizeSummary

Catalyst Pharmaceuticals has entered into a definitive agreement to be acquired by Angelini Pharma for approximately $4.1 billion in cash, with shareholders receiving $31.50 per share. This transaction represents a significant premium and marks a pivotal moment for the company.

check_boxKey Events

• Definitive Merger Agreement

  Catalyst Pharmaceuticals will be acquired by Angelini Pharma S.p.A. for an all-cash consideration.

• Per-Share Consideration

  Shareholders will receive $31.50 in cash for each outstanding share.

• Total Equity Value

  The acquisition is valued at approximately $4.1 billion USD.

• Significant Premium

  The offer represents a 21% premium to Catalyst's unaffected closing share price on April 22, 2026, and a 28% premium to the 30-day volume-weighted average trading price.

auto_awesomeAnalysis

This 8-K filing confirms the definitive agreement for Angelini Pharma to acquire Catalyst Pharmaceuticals, a highly significant event for investors. The all-cash offer of $31.50 per share provides immediate and certain value to shareholders, representing a substantial premium over recent trading prices. This acquisition allows Angelini Pharma to enter the U.S. market and expand its presence in neurological rare diseases. The simultaneous announcement of a settlement in the FIRDAPSE patent litigation, securing exclusivity until at least January 2035, further de-risks Catalyst's core asset and strengthens the value proposition for the acquirer. The unanimous board approval and voting agreements from key insiders indicate strong support for the transaction. Investors should monitor the progress of regulatory approvals and the shareholder vote, though the voting agreements suggest a high likelihood of approval.